|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Amgen beat second-quarter expectations, but its 2017 earnings guidance still lagged some views.
IBD's 439-company Biotech industry group is now ranked fourth out of 197. How far can the rally go?